BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 03, 2003
 |  BioCentury  |  Product Development

Nastech keeps a light on for Pharmacia

The return of product rights to satisfy antitrust considerations generally says little one way or another about the product's actual value. But in the case of last week's return of intranasal apomorphine to Nastech Pharmaceutical Co. Inc., the deal structure makes clear that Pharmacia Corp. still likes the sexual dysfunction treatment.
NSTK and PHA partnered to develop the compound exactly a year ago. Last week, the Federal Trade Commission (FTC) ordered PHA to return the rights to NSTK because Pfizer Inc., which is acquiring PHA, already markets Viagra sildenafil to treat erectile dysfunction (ED).
Last week's deal includes a provision that if the merger doesn't happen, PHA (Peapack, N.J.) will get the intranasal apomorphine product back. "In the event that the merger never goes through, Pharmacia would like to have it back," said Steven Quay, NSTK...

Read the full 675 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >